[CAR T-cell therapy for malignant lymphoma].

Area of Science:

• Oncology
• Immunotherapy

Context:

• Novel targeted therapies for B-cell lymphoma pathogenesis.
• CD19-targeted chimeric antigen receptor (CAR) T-cell therapies demonstrate significant efficacy in clinical trials for relapsed/refractory B-cell lymphomas.
• Three CAR T-cell products are approved and available in Japan.

Purpose:

• To review clinical trial results and real-world evidence (RWE) of CAR T-cell therapy in B-cell lymphoma.
• To discuss the broadening role of CAR T-cell therapy in clinical practice.
• To highlight the need for risk stratification and management strategies for refractory cases.

Summary:

• CAR T-cell therapy exhibits comparable efficacy in real-world practice as in clinical trials, even in diverse patient populations.
• Real-world evidence supports the effectiveness of CAR T-cell therapy in treating B-cell lymphomas.
• Despite successes, approximately 50% of patients experience disease progression, necessitating further investigation into treatment optimization.

Impact:

• CAR T-cell therapy is expanding its role in B-cell lymphoma treatment due to proven efficacy.
• Real-world data validates the effectiveness of CAR T-cell therapy in a broader patient demographic.
• Urgent need identified for improved risk stratification and management protocols for patients with refractory B-cell lymphoma post-CAR T-cell therapy.